Shots:

• The companies collaborated to evaluate ficlatuzumab + Erbitux in registrations study in patients with recurrent or metastatic HNSCC. The study is expected to initiate in H1’23
• Merck KGaA will provide cetuximab clinical drug supply in all countries outside of the US & Canada for AVEO’s registrational study to evaluate ficlatuzumab + cetuximab for HPV negative R/M HNSCC. AVEO will be the study sponsor & will be responsible for costs associated with trial execution
• The company is planning to initiate the manufacturing of ficlatuzumab clinical supply in Q2'22. Ficlatuzumab is being evaluated in HNSCC & metastatic PDAC & has received FTD from the US FDA for recurrent or metastatic HNSCC

Ref: Globe Newswire | Image: Merck KGaA